8-K: Abeona Therapeutics to Sell Priority Review Voucher for $155 Million

Abeona Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $155 million.

Summary

• Abeona Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $155 million.
• The PRV was awarded following FDA approval of ZEVASKYN (prademagene zamikeracel) on April 28, 2025.
• The sale is subject to customary closing conditions, including Hart-Scott-Rodino Antitrust Improvements Act requirements.
• Abeona expects to have sufficient cash for over two years of operating expenses from the proceeds, not accounting for ZEVASKYN sales.
• The company anticipates becoming profitable in early 2026, with ZEVASKYN becoming available to treat patients beginning in the third quarter of 2025.
• Stifel and Jefferies served as financial advisors on the transaction.

Sentiment

Score: 8

Explanation: The announcement is positive due to the significant cash infusion from the PRV sale and the expectation of profitability in the near future. This reduces financial risk and supports the company's operations.

Positives

• The $155 million from the PRV sale will provide Abeona with over two years of operating cash, excluding ZEVASKYN sales.
• Abeona anticipates becoming profitable in early 2026.
• ZEVASKYN, the first and only autologous cell-based gene therapy for wounds in RDEB patients, is expected to be available in Q3 2025.
• FDA approval of ZEVASKYN on April 28, 2025.

Risks

• The sale is subject to customary closing conditions, including the expiration or termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period, which could delay or prevent the transaction.
• The company's forward-looking statements are subject to various risks and uncertainties, including the ability to generate commercial sales of ZEVASKYN, enroll patients in clinical trials, and obtain regulatory approvals.

Future Outlook

Abeona expects to have sufficient cash for over two years of operating expenses from the PRV sale and anticipates becoming profitable in early 2026, with ZEVASKYN becoming available in Q3 2025.

Management Comments

• Joe Vazzano, Chief Financial Officer of Abeona, stated that the company will have sufficient cash for more than two years of operating expenses without needing a capital infusion, not accounting for ZEVASKYN sales.
• Joe Vazzano also mentioned that they anticipate becoming profitable in early 2026.

Industry Context

The sale of a Priority Review Voucher is a relatively common occurrence in the biopharmaceutical industry, as it provides a non-dilutive source of funding for companies developing treatments for rare pediatric diseases. The proceeds can be used to further research and development efforts or to support commercialization activities.

Comparison to Industry Standards

• The sale price of $155 million for the PRV is within the typical range for such vouchers, although prices can vary depending on market conditions and the specific characteristics of the voucher.
• Comparable companies that have sold PRVs include BioMarin Pharmaceutical and United Therapeutics, with sale prices ranging from $100 million to $150 million in recent years.
• The use of Stifel and Jefferies as financial advisors is also common in these types of transactions, as they have experience in the biopharmaceutical industry and can help companies navigate the sale process.

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and potential for profitability.
• Employees will have increased job security due to the company's improved financial position.
• Patients with RDEB will have access to ZEVASKYN, a new treatment option.

Next Steps

• Closing of the PRV sale transaction, subject to customary conditions.
• Commercial launch of ZEVASKYN in the third quarter of 2025.
• Continued development of AAV-based gene therapies for ophthalmic diseases.

Key Dates

Keywords

Priority Review Voucher, ZEVASKYN, Abeona Therapeutics, PRV, FDA, Sale, Profitability, RDEB, Gene Therapy